Zilbrysq (Zilucoplan) for Myasthenia Gravis | MGteam

Connect with others who understand.

sign up Log in
About MGteam
Powered By

Overview
Zilbrysq is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with myasthenia gravis who test positive for anti-acetylcholine receptor antibodies. This means that the body has antibodies that mistakenly attack muscle receptors, causing communication problems between nerves and muscles. Zilbrysq is also referred to by its drug name, zilucoplan.

Zilbrysq is used as a targeted therapy to treat adults with myasthenia gravis. It is a member of a class of drugs called complement inhibitors. Zilbrysq is believed to work by blocking C5, a protein in the immune system that is involved with the symptoms of myasthenia gravis.

How do I take it?
Prescribing information states that Zilbrysq is to be administered with the help of a health care professional. After training on subcutaneous (under the skin) injection techniques, individuals can self-inject Zilbrysq. Use Zilbrysq exactly as prescribed by your health care provider.

Zilbrysq comes in single-dose prefilled syringes.

Side effects
The FDA-approved label for Zilbrysq lists common side effects including injection site reactions, upper respiratory tract infections, and diarrhea.

Rare but serious side effects listed for Zilbrysq include pancreatitis (inflammation of the pancreas), other pancreatic problems, and pain in your stomach area that will not go away.

Zilbrysq increases your chance of getting serious and life-threatening meningococcal infections. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early. You need to receive both types of meningococcal vaccines (for both serogroup B infections and serogroup A, C, W, and Y infections) at least two weeks before your first Zilbrysq dose if you haven’t already received these vaccinations.

For more details about this treatment, visit:

Zilbrysq — Drugs.com
https://www.drugs.com/zilbrysq.html

FDA Approves Zilbrysq as First Once-Daily Subcutaneous C5 Inhibitor for Generalized Myasthenia Gravis — Practical Neurology
https://practicalneurology.com/news/fda-approve...

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in